NCT05751018 2025-12-02
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06563999 2024-12-10
NUMER
Sun Yat-sen University
Phase 2 Recruiting
NCT04144569 2024-09-19
PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT06185400 2023-12-29
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04063462 2019-08-21
Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02535507 2015-08-28
Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
Tongji University
Phase 2 Unknown